Prostate Cancer News on BioPortfolio

Model Can Predict Survival in Nonmetastatic Prostate Cancer

TUESDAY March 12 2019 An individualized multivariable model can predict survival in patients with nonmetastatic prostate cancer PCa according to a study published online March 12 in PLOS Medicine.David R. Thurtle B.M.B.S. from the...

Bayer files prostate cancer drug darolutamide with EU regulators

After filings in the US and Japan Bayer has submitted data to European regulators for its prostate cancer drug darolutamide.This is the third filing in two weeks for darolutamide meaning that the drug is now under review with regulators from th...

Darolutamide submitted for EU approval

Orion Corporation and Bayer have submitted a marketing application in Europe for use of darolutamide in patients with a certain type of prostate cancer.

Testosterone Replacement in Prostate Cancer Debated

New evidence on the controversial topic of testosterone replacement in men with prostate cancer once thought to be taboo will be presented at the upcoming European Association of Urology Congress. Medscape Medical News